RxDoctor Payments Data

Tonya Henderson, APRN

Family · Bartlesville, OKNPI 1073194742

Payments from drug & device makers

$927in general payments, 2019–2025

Across 16 payments — averaging $57.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$420
  • AbbVie$127
  • Eisai Inc.$112
  • Amgen$74
  • Johnson & Johnson$72
  • Exact Sciences$45
  • plus $77 from 3 others

What the payments were for

  • Food & beverage$927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$927 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$34,231
Medicare patients
227
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$59,231
FarxigaDapagliflozin Propanediol28$20,026
JardianceEmpagliflozin17$17,797
EliquisApixaban22$17,656
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,676
MounjaroTirzepatide16$15,553
TrulicityDulaglutide17$15,316
Rosuvastatin Calcium94$3,409
Novolog FlexpenInsulin Aspart14$2,604
Albuterol Sulfate HfaAlbuterol Sulfate87$2,026
Atorvastatin Calcium83$1,283
Olmesartan Medoxomil22$1,263
SynthroidLevothyroxine Sodium23$1,106
Gabapentin92$1,088
Omeprazole68$923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$45$59,23157 claims
AstraZenecaFarxiga$420$20,02628 claims
Boehringer IngelheimJardiance$17$17,79717 claims
GSKTrelegy Ellipta$15$16,67626 claims
AbbVieSynthroid$127$1,10623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,026 family providers in Oklahoma.

Other family in Bartlesville

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →